FDA Approves First Oral Therapy for Dermatomyositis in Adults

The FDA approved brepocitinib (Lisraya), the first oral therapy specifically indicated for treating adult dermatomyositis, a rare autoimmune disease. The approval follows positive phase 3 trial results demonstrating significant benefit and safety profile compared to placebo and current treatments.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 27 Aug 2026 and 28 Aug 2026.